Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

NCT00171587 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors
Neoplasm Metastasis

Interventions

DRUG: PTK787/ZK 222584 (vatalanib)

Sponsor

Novartis

Collaborators

[object Object]